Lilly says it's confident in weight-loss pill supply ahead of U.S. approval

Eli Lilly said on Monday it is confident about the supplies of its weight-loss pill orforglipron ahead of its anticipated U.S. approval in the coming months.

Reuters • 18 hours ago

Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab

Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San Francisco Bay area over five years which will use Nvidia's newest generation Vera Rubin AI chips, the firms said on Monday.

Reuters • 19 hours ago

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather and then heading higher.

24/7 Wall Street • 20 hours ago

Eli Lilly CFO on $1 Billion AI Drug Lab Investment

Eli Lilly Chief Financial Officer Lucas Montarce says the company's weight-loss pill is on track to be approved in the US as early as the second quarter of this year. He speaks to Katie Greifeld at the JPMorgan Healthcare Conference in San Francisco.

Bloomberg Markets and Finance • 17 hours ago

Eli Lilly and Nvidia Make $1 Billion AI Bet to Revolutionize Pharma's Future

One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery.

24/7 Wall Street • 16 hours ago

Abivax shares soar 23% as media report reignites M&A chatter

Shares in Abivax soared 23%, exceeding 121 euros, on Monday after a media report said U.S. pharma giant Eli Lilly was still interested in buying the French biotech company.

Reuters • Jan 12, 2026

France has had no request for investment approval in biotech Abivax - official

France's finance ministry has received no request seeking investment approval in Abivax and has had no contact with Eli Lilly , a ministry official said on Monday, following media reports that the U.S. pharma giant was still interested in buying the French biotech firm.

Reuters • 19 hours ago

Here's Why Eli Lilly (LLY) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • 18 hours ago

Eli Lilly (LLY) Laps the Stock Market: Here's Why

Eli Lilly (LLY) concluded the recent trading session at $1, signifying a +1.64% move from its prior day's close.

Zacks Investment Research • 10 hours ago

Abivax stock rockets 30% on Eli Lilly takeover speculation

Abivax stock (EPA: ABVX) surged roughly 30% in early Paris trading Monday after French media reported that US pharmaceutical giant Eli Lilly was preparing a €15 billion ($17.5 billion) acquisition offer for the French biotech.

Invezz • 19 hours ago